BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33159174)

  • 1. Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT.
    Zhao YY; Jia J; Zhang JJ; Xun YP; Xie SJ; Liang JF; Guo HG; Zhu JZ; Ma SL; Zhang SR
    Acta Pharmacol Sin; 2021 Aug; 42(8):1288-1297. PubMed ID: 33159174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways.
    Jiang M; Zhou LY; Xu N; An Q
    Thorac Cancer; 2019 Jun; 10(6):1319-1333. PubMed ID: 31055884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking M2 muscarinic receptor signaling inhibits tumor growth and reverses epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC).
    Zhao Q; Gu X; Zhang C; Lu Q; Chen H; Xu L
    Cancer Biol Ther; 2015; 16(4):634-43. PubMed ID: 25778781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of histamine receptor 3 suppresses glioblastoma tumor growth, invasion, and epithelial-to-mesenchymal transition.
    Lin JJ; Zhao TZ; Cai WK; Yang YX; Sun C; Zhang Z; Xu YQ; Chang T; Li ZY
    Oncotarget; 2015 Jul; 6(19):17107-20. PubMed ID: 25940798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling.
    Liu X; Sun L; Zhang S; Zhang S; Li W
    J Cell Physiol; 2020 Nov; 235(11):7747-7756. PubMed ID: 31681988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways.
    Yue SJ; Zhang PX; Zhu Y; Li NG; Chen YY; Li JJ; Zhang S; Jin RY; Yan H; Shi XQ; Tang YP; Duan JA
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31181779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesol abrogates epithelial to mesenchymal transition process through regulating Akt/mTOR pathway.
    Lee JH; Chinnathambi A; Alharbi SA; Shair OHM; Sethi G; Ahn KS
    Pharmacol Res; 2019 Dec; 150():104504. PubMed ID: 31678208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardamonin inhibits the proliferation and metastasis of non-small-cell lung cancer cells by suppressing the PI3K/Akt/mTOR pathway.
    Zhou X; Zhou R; Li Q; Jie X; Hong J; Zong Y; Dong X; Zhang S; Li Z; Wu G
    Anticancer Drugs; 2019 Mar; 30(3):241-250. PubMed ID: 30640793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
    Piao J; Chen L; Quan T; Li L; Quan C; Piao Y; Jin T; Lin Z
    Oncotarget; 2016 Sep; 7(37):60169-60180. PubMed ID: 27507059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
    Wang J; Ma S; Chen X; Zhang S; Wang Z; Mei Q
    Invest New Drugs; 2019 Oct; 37(5):828-836. PubMed ID: 30456603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
    Wang ZL; Fan ZQ; Jiang HD; Qu JM
    Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
    Zhao L; Zhang J; Fan Y; Li Y
    Med Sci Monit; 2019 Oct; 25():7864-7871. PubMed ID: 31631173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ginkgolic Acid Inhibits Invasion and Migration and TGF-β-Induced EMT of Lung Cancer Cells Through PI3K/Akt/mTOR Inactivation.
    Baek SH; Ko JH; Lee JH; Kim C; Lee H; Nam D; Lee J; Lee SG; Yang WM; Um JY; Sethi G; Ahn KS
    J Cell Physiol; 2017 Feb; 232(2):346-354. PubMed ID: 27177359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.